[CAS NO. 87099-85-2] Spicamycin
PRODUCTS SPECIFICATIONS [87099-85-2]
DESCRIPTION [87099-85-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 621.77 |
| Molecular Formula | C30H51N7O7 |
| SMILES | OC[C@H](O)[C@]([C@H](NC(CNC(CCCCCCCCCCCCC(C)C)=O)=O)[C@@H](O)[C@H]1O)([H])O[C@@H]1NC2=C3C(N=CN3)=NC=N2 |
Summary
Spicamycin, an adenine nucleoside antibiotic with antifungal and antitumor activities. Spicamycin is also a potent inducer of differentiation of myeloid leukemia cells. Spicamycin induces apoptosis in NB4 cells via down-regulation of Bcl-2 expression and modulation of PML protein [1] [2] .
IC50 & Target
|
Bcl-2 |
In Vitro
Spicamycin (10-160 ng/mL; 0-5 d) potently inhibits cell proliferation and viability of NB4, NKM-1, and HL-60 cells
[1]
.
Spicamycin (20 ng/mL, 80 ng/mL; 48 h) induces apoptosis in NB4, HL-60 and NKM-1 cells
[1]
.
Spicamycin (20 ng/mL, 40 ng/mL; 36 h) down-regulates the Bcl-2 expression in NB4 cells
[1]
.
Spicamycin (2.5-640 ng/mL) shows anti-microbial activity against
Saccharomyces cerevisiae
ATCC 9763,
Candida utilis
IFO 0396, and
Trichophyton mentagrophytes
with MIC values of 25μg/mL, 25μg/mL, and 1.56 μg/mL, respectively
[2]
。
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | NB4, HL-60, NKM-1, NOP-1 and Daudi cells |
| Concentration: | 10 ng/mL, 20 ng/mL, 40 ng/mL, 80 ng/mL, 160 ng/mL |
| Incubation Time: | 0, 1, 2, 3, 4, and 5 days or 72 hours |
| Result: |
Completely inhibited cell proliferation and viability of NB4 and NKM-1 at 40 ng/mL, of HL-60 at 80 ng/mL, but failed to inhibit NOP-1 and Daudi cells at higher dose of 160 ng/mL.
Inhibited cells viability of IC 50 s of 18.2 ng/mL, 28.6 ng/mL, 23.8 ng/mL, 74.9 ng/mL, and 37.4 ng/mL, respectively. |
Western Blot Analysis [1]
| Cell Line: | NB4 cells |
| Concentration: | 20 ng/mL, 40 ng/mL |
| Incubation Time: | 36 hours |
| Result: | Reduced the Bcl-2 expression without affecting Bcl-xL and Bax expression. |
In Vivo
Spicamycin (0.125-2 mg/kg; i.p.; once daily for 9 d) shows anti-tumor activity against P388 Mouse Leukemia model
[2]
.
Spicamycin shows an LD
50
value of 40 mg/kg (i.p.) in mice
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | P388 Mouse Leukemia model [2] |
| Dosage: | 0.125, 0.25, 0.5, 1.0, and 2.0 mg/kg |
| Administration: | Intraperitoneal injection; once daily for 9 days |
| Result: |
Showed no biotoxicity at dose below 2.0 mg/kg.
|
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Zhang WJ, et al. Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia protein. Jpn J Cancer Res. 2000 Jun;91(6):604-11.
- [2] Hayakawa Y, et al. Spicamycin, a new differentiation inducer of mouse myeloid leukemia cells (Ml) and human promyelocytic leukemia cells (HL-60)[J]. Agricultural and biological chemistry, 1985, 49(9): 2685-2691.